Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression
No controlled human trials confirm the frequency or severity of the symptoms
And, of course, this is all provided for information purposes only (in case you get asked about this on Jeopardy) and again, always speak with your medical doctor before starting anything new: Dosage : A common starting dose for DSIP is between 100 and 200 mcg per administration, with some individuals titrating up to 400 mcg or more depending on their response and tolerance
When you think of antioxidants, you may think of vitamin C, A, and E
There is no published human safety or efficacy data, no reproductive- or developmental-toxicology research, no studies in hepatic or renal impairment, and no drug-interaction studies
The length and gauge of the needle may vary depending on the patients muscle mass and the injection site